Department of Hematology and Oncology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Medicine (Baltimore). 2023 Feb 22;102(8):e32899. doi: 10.1097/MD.0000000000032899.
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy, immunotherapy, or molecularly targeted therapy is used to treat NSCLC. Nevertheless, many patients who accept surgery likely develop distant metastases or local recurrence. In recent years, targeted treatments and immunotherapy have achieved improvement at a breakneck pace. Therapy must be customized for each patient based on the specific medical condition, as well as other variables. It is critical to have an accurate NSCLC sub-classification for tailored treatment, according to the latest World Health Organization standards.
肺癌仍然是癌症死亡的主要原因。非小细胞肺癌（NSCLC）是最常见的肺癌亚型。手术、放疗、化疗、免疫疗法或分子靶向治疗用于治疗 NSCLC。然而，许多接受手术的患者可能会发生远处转移或局部复发。近年来，靶向治疗和免疫疗法取得了飞速的进展。治疗必须根据每个患者的具体病情以及其他变量进行定制。根据最新的世界卫生组织标准，对 NSCLC 进行准确的亚分类对于制定治疗方案至关重要。
